vobramitamab duocarmazine
vobramitamab duocarmazine: 4 clinical trials tracked.
vobramitamab duocarmazine evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about vobramitamab duocarmazine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (4)
A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Primary endpoint: Objective Response Rate (ORR)
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Primary endpoint: Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Primary endpoint: Number of participants with adverse events (AEs)
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Primary endpoint: Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03